The Calpain hypothesis of neurodegeneration: Evidence for a common cytotoxic pathway

Neuroscientist

Volumn 3, Issue 5, 1997, Pages 314-327

  Bartus, Raymond T ^a,b  

^a ALKERMES INC   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Alzheimer's disease; Calcium dysfunction; Glutamate toxicity; Ischemia; Neurodegenerative diseases; Parkinson's disease; Spinal cord injury; Stroke; Traumatic brain injury

Indexed keywords

EID: 0001454672     PISSN: 10738584     EISSN: None     Source Type: Journal    
DOI: 10.1177/107385849700300513     Document Type: Review

References (83)

1. Sorimachi H, Saido TC, Suzuki K. New era of calpain research. Discovery of tissue-specific calpains. FEBS Lett 1994;343:1-5.
2. Melloni E, Pontremoli S. The calpains. Trends Neurosci 1989; 12:438-444.
3. Seubert P, Lynch G. Plasticity to pathology: brain calpains as modifiers of synaptic structure. In: Mellgren RL, Murachi T, editors. Intracellular calcium dependent proteolysis. Boca Raton (FL): CRC Press; 1990. p. 251-263.
4. Suzuki K, Ohno S. Calcium activated neutral protease structure-function relationship and functional implications. Cell Struct Funct 1990;156:1-6.
5. Takahashi K. Calpain substrate specificity. In: Mellgren RL, Murachi T, editors. Intracellular calcium dependent proteolysis. Boca Raton (FL): CRC Press; 1990. p. 55-74.
6. Saido T, Sorimachi H, Suzuki K. Calpain: new perspectives in molecular diversity and physiological-pathological involvement. FASEB J 1994;8:814-822.
7. Suzuki K, Sorimachi H, Yoshizawa T, Kinbara K, Ishiura S. Calpain: novel family members, activation, and physiological function. Biol Chem Hoppe Seyler 1995;376:523-529.
8. Nixon RA. Calcium-activated neutral proteinases as regulators of cellular function: implications for Alzheimer's disease pathogenesis. Ann N Y Acad Sci 1989;568:198-206.
9. Shea TB, Cressman CM, Spencer MJ, Beermann ML, Nixon RA. Enhancement of neurite outgrowth following calpain inhibition is mediated by protein kinase C. J Neurochem 1995;517-527.
10. Lynch G, Baudry M. The biochemistry of memory: a new and specific hypothesis. Science 1984;224:1057-1063.
11. Siman R, Baudry M, Lynch G. Brain fodrin: substrate for the endogenous calcium-activated protease calpain I. Proc Natl Acad Sci U S A 1984;81:3276-3280.
12. Seubert P, Lee K, Lynch G. Ischemia triggers NMDA receptor-linked cytoskeletal proteolysis in hippocampus. Brain Res 1989; 492:366-370.
13. Bartus RT. Drugs to treat age-related neurodegenerative problems: the final frontier of medical science? J Am Geriatr Soc 1990;38: 680-695.
14. Bartus RT, Dean RL, Cavanaugh K, et al. Time-related neuronal changes following middle cerebral artery occlusion: Implications for therapeutic intervention and the role of calpain. J Cereb Blood Flow Metab 1995;15:969-979.
15. Roberts-Lewis JM, Savage MJ, Marcy VR, et al. Immunolocalization of calpain I-mediated spectrin degradation to vulnerable neurons in the ischemic gerbil brain. J Neurosci 1994;14:3934-3944.
16. Lee KS, Frank S, Vanderklish P, et al. Inhibition of proteolysis protects hippocampal neurons from ischemia. Proc Natl Acad Sci U S A 1991;88:7233-7237.
17. Wang KKW, Yuen P-W. Calpain inhibition: an overview of its therapeutic potential. TIPS 1994;15:4412-4419.
18. Seubert P, Baudry M, Dudek S, Lynch G. Calmodulin stimulates the degradation of brain spectrin by calpain. Synapse 1987;1: 20-24.
19. Choi DW. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988;1:623-624.
20. Rothman SM, Olney JW. Glutamate and pathophysiology of hypoxic-ischemic brain damage. Ann Neurol 1986;19:105-111.
21. Siesjo BK, Bengtsson F. Calcium fluxes, calcium antagonists, and calcium-related pathology in brain ischemia, hypoglycemia, and spreading depression: a unifying hypothesis. J Cereb Blood Flow Metab 1989;9:127-140.
22. Ivy GO, Seubert P, Baudry M, Lynch G. Presence of brain spectrin in dendrites of mammalian brain: technical factors involved in immunocytochemical detection. Synapse 1988;2:329-333.
23. Siman R, Baudry M, Lynch G. Brain fodrin: substrate for calpain I, an endogenous calcium-activated protease. Proc Natl Acad Sci USA 1984;81:3572-3576.
24. Hong S-C, Lanzino G, Goto Y, et al. Calcium-activated proteolysis in rat neocortex induced by transient focal ischemia. Brain Res 1994;661:43-50.
25. Yao H, Ginsberg MD, Eveleth DD, et al. Local cerebral glucose utilization and cytoskeletal proteolysis as indices of evolving focal ischemic injury in core and penumbra. J Cereb Blood Flow Metab 1995;15:398-408.
26. Hong S-C, Goto Y, Lanzino G, et al. Neuroprotection with a calpain inhibitor in a model of focal cerebral ischemia. Stroke 1994; 25:663-669.
27. Bartus RT, Hayward NJ, Elliott PJ, et al. Calpain inhibitor AK295 protects neurons from focal brain ischemia: effects of postocclusion intra-arterial administration. Stroke 1994;25:2265-2270.
28. Bartus RT, Baker KL, Heiser AD, et al. Postischemic administration of AK275, a calpain inhibitor, provides substantial protection against focal ischemic brain damage. J Cereb Blood Flow Metab 1994b;14:537-544.
29. Seubert P, Lee K, Lynch G. Ischemia triggers NMDA receptor-linked cytoskeletal proteolysis in hippocampus. Brain Res 1989; 492:366-370.
30. Saito TC, Yokota M, Nagao S, et al. Spatial resolution of fodrin proteolysis in postischemic brain. J Biol Chem 1993;268:25239-25243.
31. Bartus RT, Dean R, Mennerick S, Eveleth D, Lynch G. Temporal ordering of pathogenic events following transient global ischemia. Submitted 1997.
32. Rami A, Krieglstein J. Protective effects of calpain inhibitors against neuronal damage caused by cytotoxic hypoxia in vitro and ischemia in vivo. Brain Res 1993;609:67-70.
33. Bartus RT, Elliott PJ, Hayward NJ, et al. Calpain as a novel target for treating acute neurodegenerative disorders. Neurol Res 1995; 17:249-258.
34. McIntosh TK. Neurochemical sequelae of traumatic brain injury: therapeutic implications. Cerebrovasc Brain Metab Rev 1994;6: 109-162.
35. Hogan EL, Banik NL, Hsu CY. Experimental spinal cord injury: a critical review. Progress in Clinical Neurosciences 1986;2: 157-173.
36. Balentine JD, Hogan EL, Banik NL, Perot PL. Calcium and the pathogenesis of spinal cord injury. In: Darcy RG Jr, editor. Trauma of the central nervous system. New York, Raven Press; 1985. p. 285-295.
37. Taft WC, Yang K, Dixon CE, Hayes RL. Microtubule-associated protein 2 levels decrease in hippocampus following traumatic brain injury. J Neurotrauma 1992;9:281-290.
38. Postmantur R, Hayes RL, Dixon CE, Taft WC. Neurofilament 68 and neurofilament 200 protein levels decrease after traumatic brain injury. J Neurotrauma 1994;11:533-545.
39. Postmantur RM, Kampfl A, Liu SJ, et al. Cytoskeletal derangements of cortical neuronal processes three hours after traumatic brain injury in rats: an immunofluorescence study. J Neuropathol Exp Neurol. In press 1997.
40. Saatman KE, Bozyczko-Coyne D, Marcy V, Siman R, McIntosh TK. Prolonged calpain mediated spectrin breakdown occurs regionally following experimental brain injury in the rat. J Neuropathol Exp Neurol 1996;55:850-860.
41. Kampfl A, Whitson JS, Zhao X, Postmantur R, Clifton GL, Hayes RL. Calpain inhibitors reduce depolarization induced loss of tau protein in primary septo-hippocampal cultures. Neurosci Lett 1995;194:149-152.
42. 2-induced myelopathy in rat spinal cord. Cent Nerv Syst Trauma 1984;1:131-137.
43. Arrigoni E, Cohadon F. Calcium-activated neutral protease activities in brain trauma. Neurochem Res 1991;16:483-487.
44. Li Z, Hogan EL, Banik NL. Role of calpain in spinal cord injury: increased calpain immunoreactivity in spinal cord after compression injury in the rat. Neurochem Int 1995;27:425-432.
45. Iizuka H, Iwasaki Y, Yamamoto T, Kadoya S. Morphometric assessment of drug effects in experimental spinal cord injury. J Neurosurg 1986;65:92-98.
46. Posmantur R, Kampfl A, Siman R, et al. A calpain inhibitor attenuates cortical cytoskeletal protein loss after experimental traumatic brain injury in the rat. Neuroscience 1997;77:875-888.
47. Saatman KE, Murai H, Bartus RT, Hayward NJ, Perri BR, McIntosh TK. The calpain inhibitor, AK295, attenuates sensory/ motor and cognitive deficits following experimental brain injury in the rat. Proc Natl Acad Sci U S A 1996;93:3428-3433.
48. Lipton SA, Rosenberg PA. Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 1994;330: 613-622.
49. Saito K-I, Elce JS, Hamos JE, Nixon RA. Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer's disease: a potential molecular basis for neuronal degeneration. Proc Natl Acad Sci U S A 1993;90:2628-2632.
50. Masliah E, Iimoto DS, Saitoh T, Hansen LA, Terry RD. Increased immunoreactivity of brain spectrin in Alzheimer's disease: a marker for synapse loss? Brain Res 1990;531:36-44.
51. Nixon RA, Saito K-I, Grynspan G, et al. Calcium-activated neutral proteinase (calpain) system in aging and Alzheimer's disease. Ann N Y Acad Sci 1994;747:77-91.
52. Terry RD, Masliah E, Salmon DP, et al. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991;30:572-580.
53. Nilsson E, Alafuzoff I, Blennow K, et al. Calpain and calpastatin in normal and Alzheimer's-degenerated human brain tissue. Neurobiol of Aging 1990;11:425-431.
54. Iwamoto N, Thangnipon W, Crawford C, Emson PC. Localization of calpain immunoreactivity in senile plaques and in neurones undergoing neurofibrillary degeneration in Alzheimer's disease. Brain Res 1991;561:177-180.
55. Shimohana S, Suenaga T, Araki W, Yamaoaka Y, Shimizu K, Kimura J. Presence of calpain II immunoreactivity in senile plaques in Alzheimer's disease. Brain Res 1991;558:105-108.
56. Grynspan F, Griffin WR, Cataldo A, Katayama S, Nixon RA. Active site-directed antibodies identify calpain II as an early-appearing and pervasive component of neurofibrillary pathology in Alzheimer's disease. Brain Res. In press 1997.
57. Shea TB, Spencer MJ, Beermann ML, Cressman CM, Nixon RA. Calcium influx into human neuroblastoma cells induces ALZ-50 immunoreactivity: Involvement of calpain-mediated hydrolysis of protein kinase C. J Neurochem 1996;66:1539-1549.
58. Siman R, Card JP, Davis LG. Proteolytic processing of β-amyloid precursor by calpain I. J Neurosci 1990;10:2400-2411.
59. Li QX, Evin G, Small DH, Multhaup G, Beyreuther K, Masters CL. Proteolytic processing of Alzheimer's disease β A4 amyloid precursor protein in human platelets. J Biol Chem 1995;270: 14140-14147.
60. Mattson MP, Cheng B, Davis D, Bryant K, Lieberburg I, Rydel RE. β-amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci 1992;12:376-389.
61. Greenamyre JT, Young AB. Excitatory amino acids and Alzheimer's disease. Neurobiol Aging 1989;10:593-602.
62. Khachaturian ZS. Calcium hypothesis of Alzheimer's disease and brain aging. Ann N Y Acad Sci 1994;747:1-11.
63. Snowdon DA, Greiner LH, Mortimer JA, et al. Brain infarction and the clinical expression of Alzheimer's disease. JAMA 1997; 277:813-817.
64. Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982;217:408-417.
65. Bartus RT. Physostigmine and memory: effects in young and aged non-human primates. Science 1979;260:1087-1089.
66. Coyle JT, McKinney J, Johnston MV, Hedreen J. Synaptic neurochemistry of the basal forebrain cholinergic projection of the rat. In: Katzman R, editor. Biological aspects of Alzheimer's disease [Banbury report 15]. Cold Spring Harbor Laboratory, 1983; 233-242.
67. Bartus RT, Flicker C, Dean RL, Pontecorvo M, Figueiredo J, Fisher SK. Selective memory loss following nucleus basalis lesions: long-term behavioral recovery despite persistent cholinergic deficiencies. Pharmacol Biochem Behav 1985;23:125-135.
68. Flicker C, Dean RL, Watkins DL, Fisher SK and Bartus RT. Behavioral and neurochemical effects following neurotoxic lesions of a major cholinergic input to the cerebral cortex in the rat. Pharmacol Biochem Behav 1983;18:973-981.
69. Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology 1993;43:1609-1611.
70. Griffin WST, Sheng JG, Roberts GW, Mrak RE. Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution. J Neuropathol Exp Neurol 1995;54: 276-281.
71. Kobayashi Y, Yamamoto K, Saido T, Kawasaki H, Oppenheim JJ, Matsushima K. Identification of calcium-activated neutral protease as a processing enzyme of human interleukin 1α. Proc Natl Acad Sci U S A 1990;87:5548-5552.
72. Kobayashi Y, Oppenheim JJ, Matsushima K. Calcium-dependent binding of phosphorylated human pre-interleukin 1α to phospholipids. J Biochem 1990;107:666-670.
73. Pontremoli S, Melloni E, Damiani G, et al. Effects of a monoclonal anti-calpain antibody on responses of stimulated human neutrophils. J Biol Chem 1988;263:1915-1919.
74. Deshpande RV, Goust JM, Hogan EL, Banik NL. Calpain secreted by activated human lymphoid cells degrades myelin. J Neurosci Res 1995;42:259-265.
75. Deshpande RV, Goust J-M, Chakrabarti AK, Barbosa E, Hogan EL, Banik NL. Calpain expression in lymphoid cells: increased mRNA and protein levels after cell activation. J Biol Chem 1995; 270:2497-2505.
76. Coyle JT, Price DL, DeLong MR. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 1983;219:1184-1190.
77. Bauxbaum JD, Oishi M, Chen HI, et al. Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer β/A4 amyloid protein precursor. Proc Natl Acad Sci U S A 1992; 89:10075-10078.
78. Blandini F, Porter RH, Greenamyre JT. Glutamate and Parkinson's disease. Mol Neurobiol 1996;12:73-94.
79. Mouatt-Prigent A, Karlsson JO, Agid Y, Hirsch EC. Increased m-calpain expression in the mesencephalon of patients with Parkinson's disease but not in other neurodegenerative disorders involving the mesencephalon: a role in nerve cell death? Neuroscience 1996;73:979-987.
80. Whitaker J, Kachelhofer R, Paty D. Urinary myelin basic protein-like material as a correlate of the progression of multiple sclerosis. Ann Neurol 1995;38:625-632.
81. Ginsberg MD. Neuroprotection in brain ischemia: an update (part 1). NEUROSCIENTIST 1995;1:95-103.
82. Ginsberg MD. Neuroprotection in brain ischemia: an update (part II). NEUROSCIENTIST 1995;1:164-175.
83. Bartus RT. Calpain inhibition: a common therapeutic rationale for treating multiple neurodegenerative conditions? Bar PR, Beal MF, editors. Neuroprotection in CNS diseases: fundamental and clinical aspects. New York: Dekker; 1997. p. 71-86.